MTBVAC TB Vaccine Enters Landmark Phase 2b Trial Across Three African Countries
• The IMAGINE trial has commenced with first vaccinations of MTBVAC, a novel tuberculosis vaccine candidate, administered in South Africa on February 19, 2025, marking a significant step in combating the world's deadliest infectious disease.
• The large-scale safety and efficacy trial will enroll approximately 4,300 participants with latent TB infection across 15 sites in South Africa, Kenya, and Tanzania, evaluating MTBVAC's effectiveness in preventing active TB lung disease.
• MTBVAC, developed by Spanish researchers and Biofabri/Zendal, is the only live-attenuated TB vaccine candidate derived from Mycobacterium tuberculosis in current trials, offering potential advantages over the century-old BCG vaccine.
© Copyright 2025. All Rights Reserved by MedPath